ACOG - Earnings announcements

ZUNVEYL generated net product revenue of $3.5 million in Q1 2026, a 40% quarter-over-quarter increase Cumulative net product revenue totaled $10.3 million through first four full quarters of launch Q1 2026 bottles dispensed increased 23% quarter-over-quarter to 6,054, with March representing the strongest month of demand since launch Approximately 75% of prescribers and 81% of facilities demonstrated repeat utilization, reinforcing durable adoption trends Real-world clinical studies active, with BEACON enrolling ahead of schedule Cash and cash equivalents totaled $54 million as of March 31, 2026, supporting the Company's continued target of operating profitability in 2027 Compan

Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/. Following the release, management

Alpha Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of $10.2 million Fourth quarter bottles dispensed increased 62% quarter-over-quarter to 4,941, with December representing the strongest month since launch Executed second national PBM contract and initiating three studies to further support ZUNVEYL's positioning in long-term care Alzheimer's patients Cash and cash equivalents totaled $66 million at year-end 2025, supporting the company's continued target of operating profitability in 2027 Company to host conference call and webcast today, March 26, at 4:30 p.m. ET Alpha Cognition Inc. (ACOG: NASDA

Management to host conference call on Thursday, March 26, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its fourth quarter and full year financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/.

Key Highlights ZUNVEYL Launch Momentum: Completed the second quarter of commercialization, generating approximately $2.8 million in total revenue for the quarter. Significant Growth: 102% quarterly increase in pharmacy orders, with record prescription volumes achieved each month during the quarter. Expanding Prescriber Base: Q3 prescribers surpassed 500, representing 55% growth over the prior quarter. Disciplined Expense Management: Full-year operating spend guidance reduced to $28–30 million; the Company expects operating profitability in 2027. Strong Balance Sheet: $35.4 million in cash and cash equivalents as of September 30, 2025, excluding the October capital raise, whic

Management to host conference call on Thursday, November 13, 2025 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, 2025, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its third quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/. Following the release, m

Key Highlights ZUNVEYL Launch Momentum: Completed the first quarter of ZUNVEYL commercialization, achieving approximately $2 million in net product revenues year-to-date. Advancing ALPHA-1062: Completed pre-clinical Bomb Blast study in collaboration with the U.S. Department of Defense and the Seattle Institute of Biomedical and Clinical Research. Strong Balance Sheet: Cash and cash equivalents of $39.4 million as of June 30, 2025, supporting an estimated cash runway of approximately two years at the current utilization rate. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company") today announced its financial results for the second quarter ended June 30, 2025.

Conference Call Scheduled for August 14, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: Participant Listening: 1-877-407-9039 or 1-201-689-8470 or https://callme.viavid.com/viavid/?callme=true&passcode=13752398&h=true&info=company&r=true&B=6 - Participant

Launched ZUNVEYL (benzgalantamine) to US market on March 17, 2025 Secured business development licensing revenues of $2.6M for partnership with CMS Pharma Cash and cash equivalents of $45.5 million as of March 31, 2025, compared to $48.6 million as of December 31, 2024. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. "We closed the quarter on a strong note, launching ZUNVEYL® to the long-term care market," said Michael McFadden, Chief Executive Officer. "We feel that the company is

Conference Call Scheduled for May 15, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today will announce financial results for the first quarter ended March 31, 2025 on May 15, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the link below 15 minutes prior to the schedul

 Raised $52.8 million in gross proceeds in Q4 2024 to support the upcoming ZUNVEYL commercial launch and Nasdaq uplisting (symbol: ACOG). Completed commercial manufacturing to support the ZUNVEYL launch. Successfully completed the first phase of a pre-clinical bomb-blast study funded by a Department of Defense grant, demonstrating benzgalantamine's efficacy and safety in treating head trauma from simulated bomb blasts. Cash and cash equivalents of $48.6 million as of December 31, 2024, compared to $3.7 million as of September 30, 2024 and $1.4 million as of December 31, 2023. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cogn

Conference Call Scheduled for March 31, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the fourth quarter and full year ended December 31, 2024 on March 31, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: 1-877-407-9039 or 1-201-689-8470 Note, you can avoid long wait times for the operator by using the Call me™ feature and clicking the lin

Alpha Cognition Inc. (NASDAQ:ACOG) (CSE:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended September 30, 2024, and provided a corporate update. "The FDA approval of ZUNVEYL represents an important breakthrough for patients with Alzheimer's disease. Alpha Cognition is focused on commercial preparation in the US market and ex-US licensing opportunities to bring this important therapy to market. The team is adding important expertise in marketing, sales, product reimbursement, and medical to bring ZUNVEYL to patients in